A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
4 марта 2020 г. обновлено: Pfizer
A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
Обзор исследования
Статус
Завершенный
Условия
Вмешательство/лечение
Тип исследования
Интервенционный
Регистрация (Действительный)
190
Фаза
- Фаза 1
Контакты и местонахождение
В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.
Места учебы
-
-
Victoria
-
Melbourne, Victoria, Австралия, 3000
- Peter MacCallum Cancer Centre
-
-
-
-
BO
-
Bologna, BO, Италия, 40138
- Az. Ospedaliera-Univer. di Bologna Policlinico S. Orsola Malpighi
-
-
MI
-
Milano, MI, Италия, 20132
- Ospedale San Raffaele di Milano
-
-
-
-
California
-
Duarte, California, Соединенные Штаты, 91010
- City of Hope
-
La Jolla, California, Соединенные Штаты, 92093
- UC San Diego Moores Cancer Center
-
La Jolla, California, Соединенные Штаты, 92037-0845
- UC San Diego Moores Cancer Center-Investigational Drug Services
-
La Jolla, California, Соединенные Штаты, 92037
- UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital)
-
Los Angeles, California, Соединенные Штаты, 90095
- Ronald Reagan UCLA Medical Center, Drug Information Center
-
Los Angeles, California, Соединенные Штаты, 90095
- UCLA Hematology-Oncology Clinic
-
Los Angeles, California, Соединенные Штаты, 90095
- Research Administration Office: Clinical Research Unit
-
Los Angeles, California, Соединенные Штаты, 90095
- UCLA Bowyer Clinic
-
Palo Alto, California, Соединенные Штаты, 94304
- Stanford University Medical Center
-
Palo Alto, California, Соединенные Штаты, 94305
- Stanford University Medical Center
-
San Diego, California, Соединенные Штаты, 92103
- UC San Diego Medical Center - Hillcrest
-
Santa Monica, California, Соединенные Штаты, 90404
- Santa Monica UCLA Hematology & Oncology Clinic
-
Stanford, California, Соединенные Штаты, 94305
- Stanford University Medical Center
-
-
District of Columbia
-
Washington, District of Columbia, Соединенные Штаты, 20007
- MedStar Georgetown University Hospital
-
Washington, District of Columbia, Соединенные Штаты, 20007
- Georgetown University Medical Center Department of Pharmacy, Research
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Emory University Hospital
-
Atlanta, Georgia, Соединенные Штаты, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Соединенные Штаты, 30322
- The Emory Clinic
-
Atlanta, Georgia, Соединенные Штаты, 30322
- Winship Cancer Institute
-
Atlanta, Georgia, Соединенные Штаты, 30322
- The Emory Clinic, Building A
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Соединенные Штаты, 02115
- Brigham and Woman's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- University of Michigan Health System
-
-
Missouri
-
Creve Coeur, Missouri, Соединенные Штаты, 63141
- Siteman Cancer Center-West County
-
Saint Louis, Missouri, Соединенные Штаты, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, Соединенные Штаты, 63110
- Barnes-Jewish Hospital
-
Saint Louis, Missouri, Соединенные Штаты, 63110
- Washington University Infusion Center Pharmacy
-
Saint Louis, Missouri, Соединенные Штаты, 63110-1094
- Barnes-Jewish Hospital
-
Saint Louis, Missouri, Соединенные Штаты, 63129
- Siteman Cancer Center- South County
-
Saint Peters, Missouri, Соединенные Штаты, 63376
- Siteman Cancer Center - St. Peters
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- The University of Texas - M.D. Anderson Cancer Center
-
San Antonio, Texas, Соединенные Штаты, 78229
- South Texas Accelerated Research Therapeutics, LLC
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98109
- Seattle Cancer Care Alliance
-
Seattle, Washington, Соединенные Штаты, 98195
- University of Washington Medical Center
-
-
-
-
-
RENNES cedex 9, Франция, 35033
- Centre d'investigation Clinique
-
-
-
-
-
Akita, Япония, 010-8543
- Akita University Hospital
-
Tokyo, Япония, 135-8550
- The Cancer Institute Hospital of Japanese Foundation For Cancer Research
-
-
Chiba
-
Kashiwa, Chiba, Япония, 277-8577
- National Cancer Center Hospital East
-
-
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
18 лет и старше (Взрослый, Пожилой взрослый)
Принимает здоровых добровольцев
Нет
Полы, имеющие право на обучение
Все
Описание
Inclusion Criteria
- Portion A: Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy or B cell lymphoma, for which no curative therapy is available. Portion A expansion includes patients who have documented disease progression on a checkpoint inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose expansion stage are required to provide archival or baseline (obtained during the screening period) tumor biopsies.
- Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which no curative therapy is available. Patients enrolled in the expansion cohort must have archival tissue available, sampled within 6 months of study entry. The Expansion cohort includes patients with FL or DLBCL with relapsed or refractory disease.
- Measurable disease with at least one extranodal tumor mass >1.0 cm in the greatest transverse diameter (GTD) or in the case of malignant lymph nodes >1.5 cm in the GTD.
- ECOG performance status of ≤ 1.
- Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥100 x 109/L, hemoglobin >9.0 g/dL. For Portion B: ANC ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L, and hemoglobin ≥ 8.0 g/dL. In both cases, patients must be transfusion independent at least 14 days prior to screening.
- Serum creatinine ≤ 2 x ULN or estimated creatinine clearance ≥ 50 ml/min.
- Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome and AST and ALT ≤ 2.5 x ULN.
Exclusion Criteria
- Patients with known symptomatic brain metastases requiring steroids.
- Prior allogeneic hematopoietic stem cell transplant.
- Immunosuppressive regimens involving systemic corticosteroids within 14 days before the first dose of study treatment.
- Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation therapy within 14 days of the first dose of study drug.
- Autoimmune disorders and other diseases that compromise or impair the immune system.
- Unstable or serious concurrent medical conditions in the previous 6 months.
- Prior therapy with any anti CD137 monoclonal antibody.
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Portion A
PF-05082566 single agent in patients with advanced cancer
|
Intravenous, Dose escalation, once per month
IV, Dose escalation, once per month
|
|
Экспериментальный: Portion B
PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma
|
Intravenous, Dose escalation, once per month
IV, Dose escalation, once per month
Intravenous, 375 mg/m2, once per week for 4 weeks
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A
Временное ограничение: Cycle 1 Day 1 to Cycle 2 Day 29 in Portion A (up to 57 days, each cycle = 28 days)
|
DLT: Any of the following adverse events (AEs) occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 alone for Portion A and not related to progressive disease.
Hematologic: Grade 4 neutropenia lasting more than (>)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis.
Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT).
Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).
Each cycle=28 days.
|
Cycle 1 Day 1 to Cycle 2 Day 29 in Portion A (up to 57 days, each cycle = 28 days)
|
|
Number of Participants With DLTs in First 2 Cycles of Portion B
Временное ограничение: Cycle 1 Day 1 to Cycle 2 Day 29 in Portion B (up to 57 days, each cycle = 28 days)
|
DLT: Any of the following AEs occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 in combination with rituximab for Portion B and not related to progressive disease.
Hematologic: Grade 4 neutropenia lasting more than (>)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis.
Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT).
Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).
Each cycle=28 days.
|
Cycle 1 Day 1 to Cycle 2 Day 29 in Portion B (up to 57 days, each cycle = 28 days)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) in Portion A
Временное ограничение: Up to approximately 2 years
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.
AEs included both non-serious AEs and SAEs.
Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.
Causality of AEs was determined by the investigator.
|
Up to approximately 2 years
|
|
Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade in Portion A
Временное ограничение: Up to approximately 2 years
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.
Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).
|
Up to approximately 2 years
|
|
Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A
Временное ограничение: Up to approximately 2 years
|
Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells.
The abnormalities with at least 1 participant are presented here.
|
Up to approximately 2 years
|
|
Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A
Временное ограничение: Up to approximately 2 years
|
Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia.
The abnormalities with at least 1 participant are presented here.
|
Up to approximately 2 years
|
|
Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion A
Временное ограничение: Up to approximately 2 years
|
For vital signs in Portion A, blood pressure and pulse rate were measured.
Clinical significance was determined by the investigator.
|
Up to approximately 2 years
|
|
PF-05082566 Maximum Observed Serum Concentration (Cmax) in Portion A
Временное ограничение: Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose
|
Cmax of PF-05082566 was observed directly from data.
|
Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose
|
|
PF-05082566 Pre-dose Trough Concentration During Multiple Dosing (Ctrough) in Portion A
Временное ограничение: Day 1 pre-dose of Cycle 2
|
Ctrough of PF-05082566 was observed directly from data.
|
Day 1 pre-dose of Cycle 2
|
|
PF-05082566 Time for Maximum Observed Serum Concentration (Tmax) in Portion A
Временное ограничение: Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
Tmax of PF-05082566 was observed directly from data as time of Cmax.
|
Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
|
PF-05082566 Area Under the Serum Concentration-Time Profile (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUClast) in Portion A
Временное ограничение: Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
AUClast of PF-05082566 was determined by linear/log trapezoidal method.
|
Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
|
PF-05082566 AUC From Time 0 to Infinity (AUCinf) in Portion A
Временное ограничение: Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.
|
Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
|
PF-05082566 AUC From Time 0 to Time of Dosing Interval (AUCtau) in Portion A
Временное ограничение: Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
AUCtau of PF-05082566 was determined using linear/log trapezoidal method.
|
Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
|
PF-05082566 Clearance (CL) in Portion A
Временное ограничение: Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2. It was reported in units of milliliter per hour per kilogram (mL/hr/kg).
|
Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
|
PF-05082566 Volume of Distribution at Steady State (Vss) in Portion A
Временное ограничение: Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.
|
Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.
|
|
Number of Participants With Positive Anti-Drug Antibody (ADA) for PF-05082566 in Portion A
Временное ограничение: Up to approximately 2 years
|
ADA for PF-05082566 was detected using electrochemiluminescence assay.
Positive ADA for PF-05082566: titer>=6.23.
|
Up to approximately 2 years
|
|
Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion A
Временное ограничение: Up to approximately 2 years
|
Categorical summarization criteria for QTc interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate): 1) absolute value of >450 to <=480 milliseconds (msec), >480 to <=500 msec, >500 msec; 2) a maximum change from baseline of >30 to <=60 msec or >60 msec.
|
Up to approximately 2 years
|
|
Percentage of Participants Achieving Objective Response Per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 in Portion A
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Objective response: confirmed best overall response (BOR) of complete response (CR) or partial response (PR) per RECIST version 1.1.
BOR of CR: target lesions and non-target diseases achieved CR, without new lesions.
BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-progression of disease (non-PD), indeterminate or missing, and without new lesions.
For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: >=30% decrease under baseline of the sum of diameters of all target measurable lesions.
For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and >=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Duration of Response in Portion A
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Duration of response: the time from first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1) to the date of first documentation of objective progression of disease (PD) or death due to any cause.
Objective PD per RECIST version 1.1: >=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeters (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions.
This outcome measure reports the individual values for evaluable participants (instead of medians etc) due to the limited number of events.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Time to Response in Portion A
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Time to response: the time from Cycle 1 Day 1 to the first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1).
BOR of CR: target lesions and non-target diseases achieved CR, without new lesions.
BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-PD, indeterminate or missing, and without new lesions.
For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes decreased to normal size); PR: >=30% decrease under baseline of the sum of diameters of all target measurable lesions.
For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and >=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Progression-Free Survival in Portion A
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Progression-free survival: the time from Cycle 1 Day 1 to the date of the first documentation of objective PD or death due to any cause, whichever occurred first.
Objective PD per RECIST version 1.1: >=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm; or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Overall Survival in Portion A
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Number of Participants With Treatment-Emergent AEs and SAEs in Portion B
Временное ограничение: Up to approximately 4 years
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.
AEs included both non-serious AEs and SAEs.
Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.
Causality of AEs was determined by the investigator.
|
Up to approximately 4 years
|
|
Number of Participants With Treatment-Emergent AEs by Maximum NCI CTCAE Grade in Portion B
Временное ограничение: Up to approximately 4 years
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment.
Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).
|
Up to approximately 4 years
|
|
Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B
Временное ограничение: Up to approximately 2 years
|
Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells.
The abnormalities with at least 1 participant are presented here.
|
Up to approximately 2 years
|
|
Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B
Временное ограничение: Up to approximately 2 years
|
Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia.
The abnormalities with at least 1 participant are presented here.
|
Up to approximately 2 years
|
|
Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion B
Временное ограничение: Up to approximately 2 years
|
For vital signs in Portion B, blood pressure, pulse rate, and body temperature were measured.
Clinical significance was determined by the investigator.
|
Up to approximately 2 years
|
|
PF-05082566 Cmax in Portion B
Временное ограничение: Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
Cmax of PF-05082566 was observed directly from data.
|
Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
|
PF-05082566 Ctrough in Portion B
Временное ограничение: Day 1 pre-dose of Cycle 2
|
Ctrough of PF-05082566 was observed directly from data.
|
Day 1 pre-dose of Cycle 2
|
|
PF-05082566 Tmax in Portion B
Временное ограничение: Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
Tmax of PF-05082566 was observed directly from data as time of Cmax.
|
Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
|
PF-05082566 AUClast in Portion B
Временное ограничение: Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
AUClast of PF-05082566 was determined by linear/log trapezoidal method.
|
Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
|
PF-05082566 AUCinf in Portion B
Временное ограничение: Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose.
|
AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.
|
Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose.
|
|
PF-05082566 AUCtau in Portion B
Временное ограничение: Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
AUCtau of PF-05082566 was determined using linear/log trapezoidal method.
|
Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
|
PF-05082566 CL in Portion B
Временное ограничение: Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2.
|
Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
|
PF-05082566 Vss in Portion B
Временное ограничение: Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.
|
Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.
|
|
Rituximab Cmax and Ctrough in Portion B
Временное ограничение: Day 1 pre-dose of Cycle 2
|
Cmax and Ctrough of rituximab were observed directly from data.
|
Day 1 pre-dose of Cycle 2
|
|
Number of Participants With Positive ADA for PF-05082566 and Rituximab in Portion B
Временное ограничение: Up to approximately 2 years
|
ADA for PF-05082566 and rituximab was detected using electrochemiluminescence assay.
Positive ADA for PF-05082566: titer>=6.23.
Positive ADA for rituximab: titer>=1.88.
|
Up to approximately 2 years
|
|
Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion B
Временное ограничение: Up to approximately 2 years
|
Categorical summarization criteria for QTc interval: 1) absolute value of >450 to <=480 milliseconds (msec), >480 to <=500 msec, >500 msec; 2) a maximum change from baseline of >30 to <=60 msec or >60 msec.
|
Up to approximately 2 years
|
|
Percentage of Participants Achieving Objective Response Per Cheson 2007 Criteria in Portion B
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Objective Response in Portion B was defined as BOR of CR or PR according to Cheson 2007 criteria.
BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or >=50% decrease in the sum of the product diameters [SPD] of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion >=15 mm in greatest transverse diameter [GTD], unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Duration of Response in Portion B
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Duration of Response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from first documentation of objective response to the date of first documentation of objective PD or death due to any cause.
Objective PD per Cheson 2007 was defined as: PD of index lesions (>=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion >=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Time to Response in Portion B
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Time to response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from Cycle 1 Day 1 to the first documentation of objective response.
BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or >=50% decrease in the SPD of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion >=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Progression-Free Survival in Portion B
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Progression-free survival in Portion B was defined as the time from Cycle 1 Day 1 to the date of the first documentation of objective PD (per Cheson 2007) or death due to any cause, whichever occurred first.
Objective PD per Cheson 2007 was defined as: PD of index lesions (>=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion >=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
|
Overall Survival in Portion B
Временное ограничение: Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.
|
Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Biomarkers Linked With Immunomodulation and Cytokine Release
Временное ограничение: Days 1, 14, 29 and 57
|
This was an exploratory endpoint and no data were collected.
|
Days 1, 14, 29 and 57
|
|
Exploratory Pharmacodynamic Biomarkers
Временное ограничение: Days 1 and 21
|
This was an exploratory endpoint and no data were collected.
|
Days 1 and 21
|
|
Patient-Reported Outcomes of PF-05082566 and Rituximab When Given in Combination in Follicular Lymphoma Participants
Временное ограничение: Up to 2 years
|
This was an exploratory endpoint and was not evaluated.
Patient-reported outcome questionnaires were not completed as a result of administrative processing error.
|
Up to 2 years
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Спонсор
Публикации и полезные ссылки
Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.
Общие публикации
- Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. doi: 10.1158/1078-0432.CCR-19-2973. Epub 2020 Mar 6.
- Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, Thall AD, Gopal AK. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16.
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования (Действительный)
21 июня 2011 г.
Первичное завершение (Действительный)
20 февраля 2019 г.
Завершение исследования (Действительный)
20 февраля 2019 г.
Даты регистрации исследования
Первый отправленный
28 февраля 2011 г.
Впервые представлено, что соответствует критериям контроля качества
28 февраля 2011 г.
Первый опубликованный (Оценивать)
2 марта 2011 г.
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
17 марта 2020 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
4 марта 2020 г.
Последняя проверка
1 марта 2020 г.
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Заболевания дыхательных путей
- Заболевания иммунной системы
- Новообразования по гистологическому типу
- Новообразования
- Лимфопролиферативные заболевания
- Лимфатические заболевания
- Иммунопролиферативные заболевания
- Легочные заболевания
- Урологические новообразования
- Урогенитальные новообразования
- Новообразования по локализации
- Заболевания почек
- Урологические заболевания
- Аденокарцинома
- Новообразования железистые и эпителиальные
- Новообразования дыхательных путей
- Грудные новообразования
- Рак, Бронхогенный
- Бронхиальные новообразования
- Новообразования головы и шеи
- Нейроэктодермальные опухоли
- Новообразования, зародышевые клетки и эмбриональные
- Новообразования, нервная ткань
- Новообразования почек
- Новообразования легких
- Нейроэндокринные опухоли
- Невусы и меланомы
- Новообразования, Плоскоклеточные
- Лимфома, В-клеточная
- Лимфома
- Лимфома, фолликулярная
- Лимфома, крупная В-клеточная, диффузная
- Карцинома, почечно-клеточная
- Карцинома немелкоклеточного легкого
- Карцинома
- Лимфома, неходжкинская
- Меланома
- Карцинома, плоскоклеточный рак
- Плоскоклеточный рак головы и шеи
- Физиологические эффекты лекарств
- Противоревматические агенты
- Противоопухолевые агенты
- Иммунологические факторы
- Противоопухолевые агенты, иммунологические
- Ритуксимаб
- Антитела, моноклональные
- Иммуноглобулин G
Другие идентификационные номера исследования
- B1641001
- 2011-002799-17 (Номер EudraCT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕТ
Описание плана IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .